Synthesis and radiolabeling of a polar [125I]I-1,2,4,5-tetrazine

IF 0.9 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of labelled compounds & radiopharmaceuticals Pub Date : 2022-12-20 DOI:10.1002/jlcr.4009

Natasha Bidesi, Vladimir Shalgunov, Umberto Maria Battisti, Lars Hvass, Jesper Tranekjær Jørgensen, Christian B. M. Poulie, Andreas I. Jensen, Andreas Kjaer, Matthias M. Herth

{"title":"Synthesis and radiolabeling of a polar [125I]I-1,2,4,5-tetrazine","authors":"Natasha Bidesi, Vladimir Shalgunov, Umberto Maria Battisti, Lars Hvass, Jesper Tranekjær Jørgensen, Christian B. M. Poulie, Andreas I. Jensen, Andreas Kjaer, Matthias M. Herth","doi":"10.1002/jlcr.4009","DOIUrl":null,"url":null,"abstract":"Pretargeting imaging has gained a lot of prominence, due to its excellent bioorthogonality and improved imaging contrast compared to conventional imaging. A new iodo tetrazine (Tz) derivative has been synthesized and further developed into the corresponding iodine-125 (125I) analog (12), via the trimethylstannane precursor. Radiolabeling with either N-chlorosuccinimide or chloramine-T, in either MeCN or MeOH proceeded with a radiochemical conversion (RCC) of >80%. Subsequent deprotection only proved successful, among the tested conditions, when the radiolabeled Tz was stirred in 6-M HCl(aq.) at 60°C for 2.5 h. To the best of our knowledge, this is the first H-tetrazine labeled with iodine. In vivo investigations on the pretargeting ability of 12 are currently under way.","PeriodicalId":16288,"journal":{"name":"Journal of labelled compounds & radiopharmaceuticals","volume":"66 1","pages":"22-30"},"PeriodicalIF":0.9000,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jlcr.4009","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of labelled compounds & radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jlcr.4009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 1

Abstract

Pretargeting imaging has gained a lot of prominence, due to its excellent bioorthogonality and improved imaging contrast compared to conventional imaging. A new iodo tetrazine (Tz) derivative has been synthesized and further developed into the corresponding iodine-125 (¹²⁵I) analog (12), via the trimethylstannane precursor. Radiolabeling with either N-chlorosuccinimide or chloramine-T, in either MeCN or MeOH proceeded with a radiochemical conversion (RCC) of >80%. Subsequent deprotection only proved successful, among the tested conditions, when the radiolabeled Tz was stirred in 6-M HCl_(aq.) at 60°C for 2.5 h. To the best of our knowledge, this is the first H-tetrazine labeled with iodine. In vivo investigations on the pretargeting ability of 12 are currently under way.

Abstract Image

查看原文本刊更多论文

极性[125I]I-1,2,4,5-四嗪的合成和放射性标记

与传统成像相比，预靶成像由于其优异的生物正交性和提高的成像对比度而备受关注。合成了一种新的碘四嗪（Tz）衍生物，并通过三甲基锡前体进一步发展为相应的碘-125（125I）类似物（12）。用N-氯琥珀酰亚胺或氯胺-T在MeCN或MeOH中的放射标记进行>；80%。在测试条件中，当放射性标记的Tz在6-M HCl（水溶液）中在60°C下搅拌2.5小时时，随后的脱保护才被证明是成功的。据我们所知，这是第一个用碘标记的h-四嗪。目前正在对12的预靶向能力进行体内研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of labelled compounds & radiopharmaceuticals 医学-分析化学

CiteScore

3.30

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： The Journal of Labelled Compounds and Radiopharmaceuticals publishes all aspects of research dealing with labeled compound preparation and applications of these compounds. This includes tracer methods used in medical, pharmacological, biological, biochemical and chemical research in vitro and in vivo. The Journal of Labelled Compounds and Radiopharmaceuticals devotes particular attention to biomedical research, diagnostic and therapeutic applications of radiopharmaceuticals, covering all stages of development from basic metabolic research and technological development to preclinical and clinical studies based on physically and chemically well characterized molecular structures, coordination compounds and nano-particles.